Foveal Eversion: A Possible Biomarker of Persistent Diabetic Macular Edema
Tóm tắt
We aimed to evaluate the impact of foveal eversion on treatment response and persistent diabetic macular edema (DME). The study was designed as interventional and prospective. DME eyes were treated with ranibizumab and/or dexamethasone (DEX) implants, or with fluocinolone acetonide (FAc) implants. FAc-treated eyes were eventually retreated by additional ranibizumab injections. Main outcome measure was the relationship between foveal eversion and both clinical outcome and persistent DME. Sixty-eight DME eyes (68 patients) treated by anti-VEGF/DEX and 50 FAc-treated eyes (50 patients) were recruited. The follow-up was 16 ± 3 months. The anti-VEGF/DEX group and FAc-treated group were statistically matched for age, sex, DME duration and previous number of injections (p > 0.05). Both groups experienced statistically significant improvements of both BCVA and central macular thickness (p < 0.01) at the end of the follow-up. Persistent DME was shown by 46% of anti-VEGF/DEX eyes and 42% of FAc-treated eyes. Foveal eversion was found in 50% of anti-VEGF/DEX eyes and in 44% of FAc-treated eyes. Its presence was associated with worse anatomical and visual outcome and higher persistence of DME in both groups (p < 0.01) and with higher retreatment percentages in FAc-treated eyes (p < 0.01). Foveal eversion is associated with worse clinical and morphological outcomes in DME.
Tài liệu tham khảo
Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–94.
Romero-Aroca P, et al. Diabetic macular edema pathophysiology: vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273.
Schmidt-Erfurth U, et al. Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.
Campochiaro PA, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32.
Campochiaro PA, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-635 e622.
Alfaqawi F, et al. Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom. Eye. 2017;31(4):650–6.
Fusi-Rubiano W, et al. Treating diabetic macular oedema (DMO): real world UK clinical outcomes for the 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at 2 years. BMC Ophthalmol. 2018;18(1):62.
Bailey C, et al. Real-world experience with 0.2 mug/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom. Eye. 2017;31(12):1707–15.
Augustin AJ, et al. Three-year results from the Retro-IDEAL study: real-world data from diabetic macular edema (DME) patients treated with ILUVIEN(®) (0.19 mg fluocinolone acetonide implant). Eur J Ophthalmol. 2020;30(2):382–91.
Bressler NM, et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257–69.
Shah AR, et al. Prediction of anti-VEGF response in diabetic macular edema after 1 injection. J Vitreoretin Dis. 2017;1(3):169–74.
Chen YP, Wu AL, Chuang CC, Chen SN. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. Sci Rep. 2019;9(1):10952.
Yoshitake T, et al. Predictor of early remission of diabetic macular edema under as-needed intravitreal ranibizumab. Sci Rep. 2019;9(1):7599.
Rasti R, et al. Deep learning-based single-shot prediction of differential effects of anti-VEGF treatment in patients with diabetic macular edema. Biomed Opt Express. 2020;11(2):1139–52.
Bressler SB, et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;134(3):278–85.
Kitagawa S, et al. Better prognosis for eyes with preserved foveal depression after intravitreal ranibizumab injection for macular edema secondary to central retinal vein occlusion. Retina. 2018;38(7):1354–60.
Elaraoud I, Andreatta W, Kidess A, Bhatnagar A, Tsaloumas M, Quhill F, Yang Y. Use of flucinolone acetonide for patients with diabetic macular oedema:patient selection criteria and early outcomes in real world setting. BMC Ophthalmol. 2016;16:3.
Kiire CA, Broadgate S, Halford S, Chong V. Diabetic macular edema with foveal eversion shows a distinct cytokine profile to other forms of diabetic macular edema in patients with type 2 diabetes. Investig Ophthalmol Vis Sci. 2014;55(13):4408.
Tan GS, et al. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017;5(2):143–55.
Chakravarthy U, et al. Clinical evidence of the multifactorial nature of diabetic macular edema. Retina. 2018;38(2):343–51.
Zhang X, et al. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27.
Midena E, et al. Müller cells changes in diabetic macular edema: in vivo correlation between OCT and molecular biomarkers in human diabetics. Investig Ophthalmol Vis Sci. 2014;5(13):4429.
Coughlin BA, Feenstra DJ, Mohr S. Müller cells and diabetic retinopathy. Vis Res. 2017;139:93–100.
Reichenbach A, Bringmann A. Glia of the human retina. Glia. 2020;68(4):768–96.
Distler C, Dreher Z. Glia cells of the monkey retina-II. Müller cells. Vis Res. 1996;36(16):2381–94.